{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:47:43Z","timestamp":1790095663620,"version":"4.0.1"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study aimed to elucidate the function of NOTCH3 in pan-cancer and CRC progression, its impact on the tumor immune microenvironment, and its value as a therapeutic target and predictive biomarker.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      We performed a multi-omics analysis of NOTCH3 alterations (expression, mutation, copy number variation, methylation) using data from The Cancer Genome Atlas (TCGA). Immune cell infiltration was assessed using multiple algorithms and single-cell RNA sequencing (scRNA-seq) data from CRC patients. In vitro functional experiments, including co-immunoprecipitation, chromatin immunoprecipitation (ChIP), luciferase reporter assays, and CD8\n                      <jats:sup>+<\/jats:sup>\n                      T cell cytotoxicity co-cultures, were conducted in CRC cell line. An immune-competent mouse xenograft model was used to evaluate the efficacy of anti-NOTCH3 in combination with anti-PD-L1 therapy. Clinical validation was performed using independent immunotherapy-treated cohorts from the MSKCC database and our institutional cohort (102 patients) via immunohistochemistry and survival analysis.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>NOTCH3 is frequently altered across multiple cancers. In CRC, high\u00a0NOTCH3 expression correlated with poor survival and fostered an immunosuppressive microenvironment. Mechanistically, NOTCH3 transcriptionally upregulates the immune checkpoint molecule PVR by binding to the transcription factor RBPJ; this process is abrogated by NOTCH3 mutations (e.g., R1669H). NOTCH3-mediated PVR upregulation suppressed CD8+ T cell cytotoxicity. scRNA-seq analysis revealed enhanced PVR-TIGIT interactions between cancer and immune cells in NOTCH3-high tumors. In vivo, NOTCH3 depletion synergized with anti-PD-L1 therapy to inhibit tumor growth and increase CD8+ T cell infiltration. Clinically, NOTCH3 mutation or low expression independently predicted improved survival in immunotherapy-treated CRC and pan-cancer cohorts.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>NOTCH3 is a pivotal regulator of immune evasion in CRC via the RBPJ-PVR axis.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1741261","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:22Z","timestamp":1771824442000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["NOTCH3 attenuates cytotoxicity via RBPJ-dependent PVR upregulation to influence immunotherapy outcomes in colorectal cancer"],"prefix":"10.3389","volume":"17","author":[{"given":"Qi","family":"Ma","sequence":"first","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuning","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ning","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of Oncology, Henan Provincial People\u2019s Hospital, People\u2019s Hospital of Zhengzhou University","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ke","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fei","family":"Ma","sequence":"additional","affiliation":[{"name":"Department of General Surgery, The Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital","place":["Zhengzhou, Henan, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21834","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA: Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2021.0106","article-title":"Diagnosis and treatment of metastatic colorectal cancer: A review","volume":"325","author":"Biller","year":"2021","journal-title":"Jama"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.02261","article-title":"Randomized phase II trial of immunotherapy-based total neoadjuvant therapy for proficient mismatch repair or microsatellite stable locally advanced rectal cancer (TORCH)","volume":"42","author":"Xia","year":"2024","journal-title":"J Clin Oncol"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4","article-title":"Nivolumab plus ipilimumab versus nivolumab in microsatellite instability-high metastatic colorectal cancer (CheckMate 8HW): a randomised, open-label, phase 3 trial","volume":"405","author":"Andr\u00e9","year":"2025","journal-title":"Lancet (London England)"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2400634","article-title":"Neoadjuvant immunotherapy in locally advanced mismatch repair-deficient colon cancer","volume":"390","author":"Chalabi","year":"2024","journal-title":"New Engl J Med"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.795972","article-title":"Neoadjuvant immunotherapy for MSI-H\/dMMR locally advanced colorectal cancer: new strategies and unveiled opportunities","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"5954","DOI":"10.1038\/s41467-021-25859-y","article-title":"Phase II study of ipilimumab and nivolumab in leptomeningeal carcinomatosis","volume":"12","author":"Brastianos","year":"2021","journal-title":"Nat Commun"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0805-8","article-title":"Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers","volume":"26","author":"Chalabi","year":"2020","journal-title":"Nat Med"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30422-9","article-title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study","volume":"18","author":"Overman","year":"2017","journal-title":"Lancet Oncol"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1459","article-title":"Perivascular NOTCH3+ Stem cells drive meningioma tumorigenesis and resistance to radiotherapy","volume":"14","author":"Choudhury","year":"2024","journal-title":"Cancer Discov"},{"key":"B11","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1038\/s41419-023-05674-7","article-title":"Notch3 regulates Mybl2 via HeyL to limit proliferation and tumor initiation in breast cancer","volume":"14","author":"Brahim","year":"2023","journal-title":"Cell Death Dis"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0677","article-title":"The role of notch3 in cancer","volume":"23","author":"Aburjania","year":"2018","journal-title":"oncologist"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1111\/cas.16040","article-title":"NOTCH3 promotes docetaxel resistance of prostate cancer cells through regulating TUBB3 and MAPK signaling pathway","volume":"115","author":"Sun","year":"2024","journal-title":"Cancer Sci"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-13-2066","article-title":"Notch3 pathway alterations in ovarian cancer","volume":"74","author":"Hu","year":"2014","journal-title":"Cancer Res"},{"key":"B15","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1038\/s41419-024-07241-0","article-title":"NOTCH3 promotes Malignant progression of bladder cancer by directly regulating SPP1 and activating PI3K\/AKT pathway","volume":"15","author":"Liu","year":"2024","journal-title":"Cell Death Dis"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.167310","article-title":"LIN28B promotes cell invasion and colorectal cancer metastasis via CLDN1 and NOTCH3","volume":"8","author":"Sugiura","year":"2023","journal-title":"JCI Insight"},{"key":"B17","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1186\/s12885-023-10526-w","article-title":"Notch3 signaling promotes colorectal tumor growth by enhancing immunosuppressive cells infiltration in the microenvironment","volume":"23","author":"Huang","year":"2023","journal-title":"BMC Cancer"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-1183","article-title":"Single-cell analysis identifies NOTCH3-mediated interactions between stromal cells that promote microenvironment remodeling and invasion in lung adenocarcinoma","volume":"84","author":"Xiang","year":"2024","journal-title":"Cancer Res"},{"key":"B19","doi-asserted-by":"publisher","first-page":"4734","DOI":"10.1016\/j.cell.2021.08.003","article-title":"Spatially organized multicellular immune hubs in human colorectal cancer","volume":"184","author":"Pelka","year":"2021","journal-title":"Cell"},{"key":"B20","doi-asserted-by":"publisher","first-page":"D870","DOI":"10.1093\/nar\/gkac947","article-title":"CellMarker 2.0: an updated database of manually curated cell markers in human\/mouse and web tools based on scRNA-seq data","volume":"51","author":"Hu","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B21","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1016\/j.immuni.2022.02.005","article-title":"Mechanistic convergence of the TIGIT and PD-1 inhibitory pathways necessitates co-blockade to optimize anti-tumor CD8(+) T cell responses","volume":"55","author":"Banta","year":"2022","journal-title":"Immunity"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1093\/database\/baac083","article-title":"TFLink: an integrated gateway to access transcription factor-target gene interactions for multiple species","volume":"2022","author":"Liska","year":"2022","journal-title":"Database: J Biol Database Curation"},{"key":"B23","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","article-title":"The STRING database in 2023: protein-protein association networks and functional enrichment analyses for any sequenced genome of interest","volume":"51","author":"Szklarczyk","year":"2023","journal-title":"Nucleic Acids Res"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-12-0095","article-title":"The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data","volume":"2","author":"Cerami","year":"2012","journal-title":"Cancer Discov"},{"key":"B25","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1038\/nbt.3192","article-title":"Spatial reconstruction of single-cell gene expression data","volume":"33","author":"Satija","year":"2015","journal-title":"Nat Biotechnol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","article-title":"CellChat for systematic analysis of cell-cell communication from single-cell transcriptomics","volume":"20","author":"Jin","year":"2025","journal-title":"Nat Protoc"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2017-108","article-title":"TIMER: A web server for comprehensive analysis of tumor-infiltrating immune cells","volume":"77","author":"Li","year":"2017","journal-title":"Cancer Res"},{"key":"B28","doi-asserted-by":"publisher","DOI":"10.1038\/nmeth.3337","article-title":"Robust enumeration of cell subsets from tissue expression profiles","volume":"12","author":"Newman","year":"2015","journal-title":"Nat Methods"},{"key":"B29","doi-asserted-by":"publisher","first-page":"220","DOI":"10.1186\/s13059-017-1349-1","article-title":"xCell: digitally portraying the tissue cellular heterogeneity landscape","volume":"18","author":"Aran","year":"2017","journal-title":"Genome Biol"},{"key":"B30","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/s13073-019-0638-6","article-title":"Molecular and pharmacological modulators of the tumor immune contexture revealed by deconvolution of RNA-seq data","volume":"11","author":"Finotello","year":"2019","journal-title":"Genome Med"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1089\/omi.2011.0118","article-title":"clusterProfiler: an R package for comparing biological themes among gene clusters","volume":"16","author":"Yu","year":"2012","journal-title":"Omics: J Integr Biol"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1126\/science.1252510","article-title":"The cellular and molecular origin of tumor-associated macrophages","volume":"344","author":"Franklin","year":"2014","journal-title":"Sci (New York N.Y.)"},{"key":"B33","doi-asserted-by":"publisher","first-page":"932","DOI":"10.1038\/s41419-024-07324-y","article-title":"TRIM59\/RBPJ positive feedback circuit confers gemcitabine resistance in pancreatic cancer by activating the Notch signaling pathway","volume":"15","author":"Chen","year":"2024","journal-title":"Cell Death Dis"},{"key":"B34","doi-asserted-by":"publisher","first-page":"2310","DOI":"10.1016\/j.immuni.2024.08.016","article-title":"Notch signaling regulates macrophage-mediated inflammation in metabolic dysfunction-associated steatotic liver disease","volume":"57","author":"Guo","year":"2024","journal-title":"Immunity"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.7150\/thno.110567","article-title":"Short-term starvation inhibits CD36 N-glycosylation and downregulates USP7 UFMylation to alleviate RBPJ-maintained T cell exhaustion in liver cancer","volume":"15","author":"Pan","year":"2025","journal-title":"Theranostics"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06733-x","article-title":"Single-cell CRISPR screens in vivo map T cell fate regulomes in cancer","volume":"624","author":"Zhou","year":"2023","journal-title":"Nature"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1245","DOI":"10.1016\/j.cell.2021.02.021","article-title":"In vivo CRISPR screening reveals nutrient signaling processes underpinning CD8(+) T cell fate decisions","volume":"184","author":"Huang","year":"2021","journal-title":"Cell"},{"key":"B38","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1038\/s41389-020-00279-7","article-title":"Notch3 contributes to T-cell leukemia growth via regulation of the unfolded protein response","volume":"9","author":"Giuli","year":"2020","journal-title":"Oncogenesis"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1038\/s41388-024-03079-0","article-title":"Notch3-regulated microRNAs impair CXCR4-dependent maturation of thymocytes allowing maintenance and progression of T-ALL","volume":"43","author":"Sergio","year":"2024","journal-title":"Oncogene"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2017.10.143","article-title":"Notch signaling pathway dampens tumor-infiltrating CD8(+) T cells activity in patients with colorectal carcinoma","volume":"97","author":"Yu","year":"2018","journal-title":"Biomed pharmacother = Biomed pharmacotherapie"},{"key":"B41","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1186\/s13045-024-01578-x","article-title":"Recent developments in immunotherapy for gastrointestinal tract cancers","volume":"17","author":"Chong","year":"2024","journal-title":"J Hematol Oncol"},{"key":"B42","doi-asserted-by":"publisher","first-page":"14327","DOI":"10.1038\/s41598-024-65036-x","article-title":"NOTCH3 as a prognostic biomarker and its correlation with immune infiltration in gastrointestinal cancers","volume":"14","author":"Xu","year":"2024","journal-title":"Sci Rep"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1038\/s41422-022-00627-9","article-title":"Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response","volume":"32","author":"He","year":"2022","journal-title":"Cell Res"},{"key":"B44","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1038\/s41568-023-00560-y","article-title":"Dynamics and specificities of T cells in cancer immunotherapy","volume":"23","author":"Oliveira","year":"2023","journal-title":"Nat Rev Cancer"},{"key":"B45","doi-asserted-by":"publisher","first-page":"3882","DOI":"10.1038\/s41467-024-48073-y","article-title":"TLR agonists polarize interferon responses in conjunction with dendritic cell vaccination in Malignant glioma: a randomized phase II Trial","volume":"15","author":"Everson","year":"2024","journal-title":"Nat Commun"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20232005","article-title":"Large-scale mutational analysis identifies UNC93B1 variants that drive TLR-mediated autoimmunity in mice and humans","volume":"221","author":"Rael","year":"2024","journal-title":"J Exp Med"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.128633","article-title":"Combination of PD-L1 and PVR determines sensitivity to PD-1 blockade","volume":"5","author":"Lee","year":"2020","journal-title":"JCI Insight"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03046-w","article-title":"TIGIT antibody with PVR competitive ability enhances cancer immunotherapy and capable of eliciting anti-tumour immune memory","volume":"133","author":"Yu","year":"2025","journal-title":"Br J Cancer"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741261\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T05:27:24Z","timestamp":1771824444000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1741261\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":48,"alternative-id":["10.3389\/fimmu.2026.1741261"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1741261","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"article-number":"1741261"}}